Buscar Company's Subsidiary Armorgenix Appoints Eric Sauer as Chief Operating Officer to Drive Innovation in Natural Health and Pharmaceutical Solutions
Buscar Company (OTC:CGLD) announced the appointment of Eric Sauer as Chief Operating Officer of its subsidiary Armorgenix, where Buscar holds a 70% stake acquired in June 2025. Sauer brings over 40 years of experience in pharmacy, naturopathy, and holistic medicine.
Sauer will oversee operations, strategic planning, and expansion of Armorgenix's manufacturing capabilities, including a planned Texas facility. The appointment strengthens Buscar's diversified portfolio, which includes Eon Discovery Inc. (gold mining operations) and a 50% stake in Terramer Inc. (hemp-based bioplastics). Armorgenix focuses on enzyme-based therapies, natural remedies, and detoxification solutions, targeting the U.S. pharmaceutical market projected to reach $854.83 billion in 2025.
Buscar Company (OTC:CGLD) ha nominato Eric Sauer Chief Operating Officer della sua controllata Armorgenix, partecipata al 70% da Buscar con acquisizione avvenuta nel giugno 2025. Sauer vanta oltre 40 anni di esperienza in farmacia, naturopatia e medicina olistica.
Sauer si occuperà delle operazioni, della pianificazione strategica e dell'espansione delle capacità produttive di Armorgenix, compreso un previsto stabilimento in Texas. La nomina rafforza il portafoglio diversificato di Buscar, che comprende Eon Discovery Inc. (attività minerarie d'oro) e una partecipazione del 50% in Terramer Inc. (bioplastiche a base di canapa). Armorgenix è focalizzata su terapie enzimatiche, rimedi naturali e soluzioni di disintossicazione, mirando al mercato farmaceutico statunitense stimato a $854.83 miliardi nel 2025.
Buscar Company (OTC:CGLD) anunció el nombramiento de Eric Sauer como Director de Operaciones (COO) de su filial Armorgenix, en la que Buscar posee una participación del 70% adquirida en junio de 2025. Sauer aporta más de 40 años de experiencia en farmacia, naturopatía y medicina holística.
Sauer supervisará las operaciones, la planificación estratégica y la ampliación de la capacidad de fabricación de Armorgenix, incluido un proyecto de instalación en Texas. El nombramiento refuerza la cartera diversificada de Buscar, que incluye a Eon Discovery Inc. (operaciones mineras de oro) y una participación del 50% en Terramer Inc. (bioplásticos derivados del cáñamo). Armorgenix se centra en terapias enzimáticas, remedios naturales y soluciones de desintoxicación, dirigidas al mercado farmacéutico de EE. UU., estimado en $854.83 mil millones en 2025.
Buscar Company (OTC:CGLD)는 자회사 Armorgenix의 최고운영책임자(COO)로 Eric Sauer를 임명했다고 발표했습니다. Buscar는 2025년 6월에 인수한 70% 지분을 보유하고 있습니다. Sauer는 약학, 자연요법 및 통합의학 분야에서 40년 이상의 경험을 보유하고 있습니다.
Sauer는 Armorgenix의 운영, 전략 기획 및 제조 역량 확장(텍사스 시설 계획 포함)을 총괄합니다. 이번 임명은 금광 채굴 사업을 운영하는 Eon Discovery Inc.와 대마 기반 생분해성 플라스틱을 개발하는 Terramer Inc.의 50% 지분 등 Buscar의 포트폴리오 다각화를 강화합니다. Armorgenix는 효소 기반 치료제, 천연 치료제 및 해독 솔루션에 주력하며, 목표 시장은 2025년 $854.830억으로 추정되는 미국 제약 시장입니다.
Buscar Company (OTC:CGLD) a annoncé la nomination de Eric Sauer au poste de directeur des opérations (COO) de sa filiale Armorgenix, dans laquelle Buscar détient une participation de 70% acquise en juin 2025. Sauer apporte plus de 40 ans d'expérience en pharmacie, naturopathie et médecine holistique.
Sauer supervisera les opérations, la planification stratégique et l'extension des capacités de fabrication d'Armorgenix, y compris une installation prévue au Texas. Cette nomination renforce le portefeuille diversifié de Buscar, qui comprend Eon Discovery Inc. (exploitation minière aurifère) et une participation de 50% dans Terramer Inc. (bioplastiques à base de chanvre). Armorgenix se concentre sur les thérapies à base d'enzymes, les remèdes naturels et les solutions de détoxification, visant le marché pharmaceutique américain estimé à 854,83 milliards $ en 2025.
Buscar Company (OTC:CGLD) gab die Ernennung von Eric Sauer zum Chief Operating Officer seiner Tochtergesellschaft Armorgenix bekannt. Buscar hält eine im Juni 2025 erworbene 70%-Beteiligung. Sauer verfügt über mehr als 40 Jahre Erfahrung in Pharmazie, Naturheilverfahren und ganzheitlicher Medizin.
Sauer wird die Betriebsführung, die strategische Planung und den Ausbau der Produktionskapazitäten von Armorgenix, einschließlich einer geplanten Anlage in Texas, leiten. Die Ernennung stärkt Buscar’s diversifiziertes Portfolio, zu dem Eon Discovery Inc. (Goldbergbau) und eine 50%-Beteiligung an Terramer Inc. (hanfbasiertes Bioplastik) gehören. Armorgenix konzentriert sich auf enzymbasierte Therapien, natürliche Heilmittel und Entgiftungslösungen und zielt auf den US-Pharmamarkt, der für 2025 auf $854.83 Milliarden geschätzt wird.
- Strategic hire with 40+ years of pharmaceutical and holistic medicine expertise
- Part of expansion following recent 70% stake acquisition in Armorgenix
- Plans for new manufacturing facility in Texas
- Access to growing pharmaceutical market projected at $854.83B by 2025
- Diversified portfolio across natural resources, sustainable tech, and pharmaceuticals
- Integration challenges may arise from leadership transition
- Significant capital requirements for planned facility expansions
- Regulatory hurdles in natural health and pharmaceutical sectors
In his new role, Sauer will oversee daily operations, strategic planning, product development, and the expansion of Armorgenix's manufacturing capabilities, including the planned
"Eric Sauer's unique blend of traditional pharmaceutical knowledge and holistic expertise makes him an ideal leader for Armorgenix at this transformative stage," said Alexander Dekhtyar CEO of Buscar Company. "Under Buscar's umbrella, we are poised to scale our operations in enzyme therapy, clinical nutrition, and antiviral solutions. Eric's insights will help us integrate seamlessly with Buscar's diversified assets, driving innovation while upholding our dedication to safety and efficacy."
Sauer's career began in 1983 when he earned his pharmacy license from the
A specialist in enzyme therapy for over 20 years, Sauer holds advanced certifications in homeopathy (DHPh), homotoxicology, clinical nutrition, and darkfield microscopy. He has studied under renowned experts, including Trevor M. Cook, PhD, former supplier of homeopathic medicines to the British Royal Family, and collaborated with figures like Thomas Rau, MD, of the Paracelsus Clinic in
In 2008, Sauer received the prestigious Order of Excellence from the World Organization of Natural Medicine (WONM) and the 2008 Award Accolade at their annual conference in
"I am thrilled to join Armorgenix and contribute to a company that shares my passion for integrating natural and conventional approaches to health," said Sauer. "As part of Buscar Company, we have the resources to accelerate product development and market entry, promoting true wellness in collaboration with medical professionals and with a steadfast focus on client safety."
Sauer's community involvement includes hosting seminars on topics like autism and mercury poisoning, natural hormone replacement therapy, and cancer support groups.
This appointment enhances Armorgenix's leadership as it leverages Buscar's synergies across its subsidiaries. Buscar's Eon Discovery Inc. manages gold mining operations in
About Armorgenix
Armorgenix, based in
About Buscar Company
Buscar Company (OTC: CGLD) is a diversified holding company headquartered in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events, or developments that Armorgenix or its parent company, Buscar Company, expects, believes, or anticipates will or may occur in the future are forward-looking statements. These statements include, but are not limited to, projections regarding the impact of Eric Sauer's appointment on operational expansions, strategic planning, product development, manufacturing capabilities (including the planned
These forward-looking statements are based on management's current expectations and assumptions about future events, which are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. Actual results may differ materially from those expressed or implied in these statements due to various factors, including, but not limited to, challenges in leadership transitions and integrating new expertise, delays or failures in establishing new facilities or expanding operations, regulatory hurdles, market acceptance of products, fluctuations in the pharmaceutical and antiviral markets, competitive pressures, and general economic conditions. Additional risks are detailed in Buscar Company's filings with the Securities and Exchange Commission.
Armorgenix and Buscar Company undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.
For media inquiries, contact:
Alexander Dekhtyar, CEO
Buscar Company
Email: office@cgld.email
View original content to download multimedia:https://www.prnewswire.com/news-releases/buscar-companys-subsidiary-armorgenix-appoints-eric-sauer-as-chief-operating-officer-to-drive-innovation-in-natural-health-and-pharmaceutical-solutions-302539660.html
SOURCE Buscar Company (CGLD)
FAQ
Who is Eric Sauer and what is his role at Buscar Company (CGLD)?
What percentage of Armorgenix does Buscar Company (CGLD) own?
What are the main products and focus areas of Armorgenix under Buscar Company?
What is the projected market size for Buscar's pharmaceutical segment?
What other subsidiaries does Buscar Company (CGLD) own?
